クレアチニ
Based on 6 publication(s) in Google Scholar
Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.92%
- CAS 番号: 60-27-5
- 分子式: C4H7N3O
- 分子量:113.12
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
MedChemExpress(MCE)の使用を引用している文献 Creatinine
More- Nature. 2025 Jul;643(8070):192-200. [Abstract]
- Biomed Pharmacother. 2024 Aug 23:179:117329. [Abstract]
- Emerg Contam. 2024 Dec, 10, 4, 100351.
- Appl Surf Sci. 2018 Nov 1, 457:684-694.
- J Chromatogr B Analyt Technol Biomed Life Sci. 2024 Jun 25:1243:124210. [Abstract]
- Research Square Preprint. 2021 Aug.
Endogenous Metabolite アイソフォーム固有の製品をすべて表示
MoreiGluR アイソフォーム固有の製品をすべて表示
More
生物活性
|
Microbial Metabolite |
Human Endogenous Metabolite |
NMDA Receptor |
Creatinine (20-180 μM; 24 h) induces a hypermetabolic state in primary inguinal and epididymal adipocytes by activating the futile creatine cycle. 20 μM Creatinine activates inguinal adipocytes, while 180 μM Creatinine activates both inguinal and epididymal adipocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 wild type mouse with Chronic kidney disease (male, 8 weeks old, unilateral ureteral obstruction model)[1]
-
Dosage:0.1 g/kg
-
Administration:i.p.; daily; 7 days
-
Result:Enhanced loss of inguinal (subcutaneous) and epididymal (visceral) adipose tissues relative to UUO-only mice; increased creatine levels in both subcutaneous and visceral adipose tissues; increased the proportion of multilocular adipocytes in both subcutaneous and visceral adipose tissues; upregulated expression of Prdm16, Pgc1α, CKB, Alpl, and Cox7a genes in subcutaneous and visceral adipose tissues
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 60-27-5
-
性状 Solid
-
分子量 113.12
-
分子式 C4H7N3O
-
Color White to off-white
-
SMILES
O=C1N=C(N)N(C)C1
-
別名
Creatinine; NSC13123
-
Structure Classification
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
Nature
2025 Jul;643(8070):192-200. PMID: 39695227 -
Biomed Pharmacother
Pharmacokinetic profiling of ZCL-278, a cdc42 inhibitor, and its effectiveness against chronic kidney disease. [Abstract]2024 Aug 23:179:117329. PMID: 39180793 -
-
-
J Chromatogr B Analyt Technol Biomed Life Sci
Simultaneous determination of choline, L-carnitine, betaine, trimethylamine, trimethylamine N-oxide, and creatinine in plasma, liver, and feces of hyperlipidemic rats by UHPLC-MS/MS. [Abstract]2024 Jun 25:1243:124210. PMID: 38936270 -
溶剤 & 溶解度
H2O : 33.33 mg/mL (294.64 mM; Need ultrasonic)
DMSO : 2.5 mg/mL (22.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 33.33 mg/mL (294.64 mM); Clear solution; Need ultrasonic
純度とドキュメンテーション
-
データシート (275 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Fang J, et al. Creatinine promotes adipose tissue wasting in chronic kidney disease via creatine and futile creatine cycle. Mol Metab. 2025;98:102191. [Content Brief]
[2]. Allen PJ, et al. Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?. Neurosci Biobehav Rev. 2012;36(5):1442-1462. [Content Brief]
[3]. Polacheck I, et al. Creatinine metabolism in Cryptococcus neoformans and Cryptococcus bacillisporus. J Bacteriol. 1980;142(1):15-20. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 8.8402 mL | 44.2008 mL | 88.4017 mL | 221.0042 mL |
| 5 mM | 1.7680 mL | 8.8402 mL | 17.6803 mL | 44.2008 mL | |
| 10 mM | 0.8840 mL | 4.4201 mL | 8.8402 mL | 22.1004 mL | |
| 15 mM | 0.5893 mL | 2.9467 mL | 5.8934 mL | 14.7336 mL | |
| 20 mM | 0.4420 mL | 2.2100 mL | 4.4201 mL | 11.0502 mL | |
| H2O | 25 mM | 0.3536 mL | 1.7680 mL | 3.5361 mL | 8.8402 mL |
| 30 mM | 0.2947 mL | 1.4734 mL | 2.9467 mL | 7.3668 mL | |
| 40 mM | 0.2210 mL | 1.1050 mL | 2.2100 mL | 5.5251 mL | |
| 50 mM | 0.1768 mL | 0.8840 mL | 1.7680 mL | 4.4201 mL | |
| 60 mM | 0.1473 mL | 0.7367 mL | 1.4734 mL | 3.6834 mL | |
| 80 mM | 0.1105 mL | 0.5525 mL | 1.1050 mL | 2.7626 mL | |
| 100 mM | 0.0884 mL | 0.4420 mL | 0.8840 mL | 2.2100 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
- Creatinine
- 60-27-5
- NSC13123
- NSC 13123
- NSC-13123
- Endogenous Metabolite
- GABA Receptor
- iGluR
- Cryptococcus bacillisporus
- creatinine deiminase
- primary epididymal adipocytes
- primary inguinal adipocytes
- GABAA receptor
- NMDA receptor
- Cryptococcus neoformans
- one-carbon metabolism
- glomerular filtration rate
- UUO-induced CKD mice
- Inhibitor
- inhibitor
- inhibit